Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study.

diabetes mellitus Europe foreign-born tuberculosis

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 20 07 2018
accepted: 14 12 2018
entrez: 31 1 2019
pubmed: 31 1 2019
medline: 31 1 2019
Statut: epublish

Résumé

The growing burden of diabetes mellitus (DM) is posing a threat to global tuberculosis (TB) control. DM triples the risk of developing TB, modifies the presenting features of pulmonary TB, and worsens TB treatment outcomes. We aimed to analyze the prevalence of DM among TB patients and to describe the characteristics and clinical presentation of TB-DM patients in Europe. We performed a cross-sectional survey on the prevalence of DM among consecutively diagnosed adult TB patients in 11 European TB referral centers located in France, Germany, Greece, Italy, Russia, Slovakia, Spain, and the United Kingdom over the period 2007-2015. We also selected DM-TB cases and TB only controls with a 1:3 ratio to perform a case-control analysis, including patients selected from the countries mentioned above plus Norway and Ukraine. Among 3143 TB enrolled patients, DM prevalence overall was 10.7% and ranged from 4.4% in Greece to 28.5% in the United Kingdom. Patients' median ages ranged from 36 to 49 years, and all centers had >60% males; the proportion of foreign-born patients varied widely across sites. In the case-control study, DM was independently associated with older age and, among older patients, with being foreign-born. Among patients with pulmonary involvement, cavities on chest imaging were more frequently observed among those with DM. Diabetes mellitus represents a challenge for TB control in Europe, especially in foreign-born and in elderly patients. Specific screening strategies should be evaluated.

Sections du résumé

BACKGROUND BACKGROUND
The growing burden of diabetes mellitus (DM) is posing a threat to global tuberculosis (TB) control. DM triples the risk of developing TB, modifies the presenting features of pulmonary TB, and worsens TB treatment outcomes. We aimed to analyze the prevalence of DM among TB patients and to describe the characteristics and clinical presentation of TB-DM patients in Europe.
METHODS METHODS
We performed a cross-sectional survey on the prevalence of DM among consecutively diagnosed adult TB patients in 11 European TB referral centers located in France, Germany, Greece, Italy, Russia, Slovakia, Spain, and the United Kingdom over the period 2007-2015. We also selected DM-TB cases and TB only controls with a 1:3 ratio to perform a case-control analysis, including patients selected from the countries mentioned above plus Norway and Ukraine.
RESULTS RESULTS
Among 3143 TB enrolled patients, DM prevalence overall was 10.7% and ranged from 4.4% in Greece to 28.5% in the United Kingdom. Patients' median ages ranged from 36 to 49 years, and all centers had >60% males; the proportion of foreign-born patients varied widely across sites. In the case-control study, DM was independently associated with older age and, among older patients, with being foreign-born. Among patients with pulmonary involvement, cavities on chest imaging were more frequently observed among those with DM.
CONCLUSIONS CONCLUSIONS
Diabetes mellitus represents a challenge for TB control in Europe, especially in foreign-born and in elderly patients. Specific screening strategies should be evaluated.

Identifiants

pubmed: 30697572
doi: 10.1093/ofid/ofy337
pii: ofy337
pmc: PMC6330516
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofy337

Références

Respiration. 2001;68(6):595-600
pubmed: 11786714
Monaldi Arch Chest Dis. 2002 Oct-Dec;57(5-6):297-305
pubmed: 12814046
Q J Med. 1957 Jan;26(101):31-42
pubmed: 13420329
Int J Clin Pract. 2007 Feb;61(2):231-5
pubmed: 17166185
BMC Public Health. 2007 Oct 14;7:291
pubmed: 17935630
Epidemiol Infect. 2009 Feb;137(2):203-10
pubmed: 18559125
PLoS Med. 2008 Jul 15;5(7):e152
pubmed: 18630984
Am J Trop Med Hyg. 2008 Oct;79(4):541-4
pubmed: 18840741
Lancet Infect Dis. 2009 Dec;9(12):737-46
pubmed: 19926034
Eur Respir J. 2011 May;37(5):1269-82
pubmed: 20947679
Trop Med Int Health. 2010 Nov;15(11):1289-99
pubmed: 20955495
Trop Med Int Health. 2010 Nov;15(11):1300-14
pubmed: 20958887
Enferm Infecc Microbiol Clin. 2011 Nov;29(9):654-9
pubmed: 21723001
Diabetes Care. 2011 Dec;34(12):2530-5
pubmed: 21972407
Thorax. 2013 Mar;68(3):214-20
pubmed: 23250998
Trop Med Int Health. 2013 Jul;18(7):822-9
pubmed: 23648145
Arch Bronconeumol. 2013 Oct;49(10):421-6
pubmed: 23791382
Western Pac Surveill Response J. 2013 Mar 31;4(1):11-8
pubmed: 23908950
BMC Public Health. 2013 Oct 21;13:991
pubmed: 24144113
Eur J Microbiol Immunol (Bp). 2012 Dec;2(4):264-74
pubmed: 24265908
J Diabetes Complications. 2014 Mar-Apr;28(2):162-5
pubmed: 24461545
Lancet Diabetes Endocrinol. 2014 Sep;2(9):730-9
pubmed: 25194886
Lancet Diabetes Endocrinol. 2014 Sep;2(9):740-53
pubmed: 25194887
Ann Intern Med. 2014 Nov 4;161(9):670-1
pubmed: 25364889
PLoS One. 2014 Dec 05;9(12):e114442
pubmed: 25478954
BMC Public Health. 2015 Mar 18;15:263
pubmed: 25884596
Public Health Action. 2015 Jun 21;5(2):147-9
pubmed: 26400387
Int J Tuberc Lung Dis. 2015 Oct;19(10):1169-75
pubmed: 26459528
Public Health Action. 2014 Jun 21;4(Suppl 1):S50-2
pubmed: 26477288
Int J Tuberc Lung Dis. 2015 Dec;19(12):1507-12
pubmed: 26614193
Int J Tuberc Lung Dis. 2016 Jun;20(6):771-7
pubmed: 27155180
Eur Respir J. 2016 Jul;48(1):264-8
pubmed: 27174884
PLoS Med. 2016 Aug 09;13(8):e1002072
pubmed: 27505150
New Microbiol. 2016 Oct;39(4):264-268
pubmed: 27727403
Infection. 2017 Jun;45(3):283-290
pubmed: 27866367
Int J Infect Dis. 2017 Mar;56:45-53
pubmed: 28153793
Lung. 2017 Apr;195(2):209-215
pubmed: 28184994
PLoS One. 2017 Apr 21;12(4):e0175925
pubmed: 28430796
Chest. 2017 Jul;152(1):165-173
pubmed: 28434936
Eur Respir J. 2017 Jul 20;50(1):
pubmed: 28729474
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):7-16
pubmed: 29297421

Auteurs

Monica Sane Schepisi (M)

Clinical Epidemiology Unit, National Institute for Infectious Diseases L. Spallanzani - IRCCS, Rome, Italy.

Assunta Navarra (A)

Clinical Epidemiology Unit, National Institute for Infectious Diseases L. Spallanzani - IRCCS, Rome, Italy.

M Nieves Altet Gomez (MN)

Unidad de Tratamiento Directamente Observado de la Tuberculosis "Servicios Clínicos," Barcelona, Spain.

Andrii Dudnyk (A)

Tuberculosis, Clinical Immunology & Allergy Department, National Pirogov Memorial Medical University, Vinnytsia, Ukraine.

Anne Margarita Dyrhol-Riise (AM)

Department of Infectious Diseases, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Department of Clinical Science, University of Bergen, Norway.

Jaime Esteban (J)

Departamento de Microbiología Clínica, Fundación Jiménez Díaz, Madrid, Spain.

Pier Francesco Giorgetti (PF)

Clinica di Malattie Infettive e Tropicali, A. O. Spedali Civili di Brescia e Università di Brescia, Brescia, Italy.

Gina Gualano (G)

Clinical Department, National Institute for Infectious Diseases L. Spallanzani - IRCCS, Rome, Italy.

Lorenzo Guglielmetti (L)

Sanatorium, Centre Hospitalier de Bligny Briis-sous-Forges, Paris, France.
APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
Sorbonne Université, Unité 1135, Team E13 (Bactériologie), CR7 INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.

Jan Heyckendorf (J)

Research Center Borstel. German Center for Infection Research (DZIF), Borstel, Germany.

Anna Kaluzhenina (A)

Department of Phthisiopulmonology, Volgograd State Medical University, Volgograd, Russian Federation.

Berit Lange (B)

Infectious Disease Division, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.
Center for Chronic Immunodeficiency, Faculty of Medicine, Medical Center, University of Freiburg, Germany.

Christoph Lange (C)

Research Center Borstel. German Center for Infection Research (DZIF), Borstel, Germany.

Katerina Manika (K)

Respiratory Infections Unit, Pulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Thessaloniki, Greece.

Jalal Miah (J)

Division of Infection, Barts Health NHS Trust, London, United Kingdom.

Zorica Nanovic (Z)

Institute of Lung Diseases and Tuberculosis - Skopje, Institute of Lung Diseases and Tuberculosis - Skopje, Skopje, FYROM (Macedonia).

Emanuele Pontali (E)

Divisione di Malattie Infettive, Ospedale Galliera - Genova, Genova, Italy.

Monica Rios Prego (MR)

Enfermedades Infecciosas, Medicina Interna, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.

Ivan Solovic (I)

Catholic University Ruzomberok, Slovakia.

Simon Tiberi (S)

Division of Infection, Barts Health NHS Trust, London, United Kingdom.

Fabrizio Palmieri (F)

Clinical Department, National Institute for Infectious Diseases L. Spallanzani - IRCCS, Rome, Italy.

Enrico Girardi (E)

Clinical Epidemiology Unit, National Institute for Infectious Diseases L. Spallanzani - IRCCS, Rome, Italy.

Classifications MeSH